Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy of single-agent ibrutinib over ofatumumab in patients with relapsed/refractory CLL/SLL, including those with high-risk features. Here we report the final analysis from RESONATE with median follow-up on study of 65.3 months (range, 0.3-71.6) in the ibrutinib arm. Median progression-free survival (PFS) remained significantly longer for Trial Registration: clinicaltrials.gov identifier: NCT01578707.
patients randomized to ibrutinib vs ofatumumab (44.1 vs 8.1 months; hazard ratio [HR]: 0.148; 95% confidence interval [CI]: 0.113-0.196; P˂.001). The PFS benefit with ibrutinib vs ofatumumab was preserved in the genomic high-risk population with del(17p), TP53 mutation, del(11q), and/or unmutated IGHV status (median PFS 44.1 vs 8.0 months; HR: 0.110; 95% CI: 0.080-0.152), which represented 82% of patients. Overall response rate with ibrutinib was 91% (complete response/complete response with incomplete bone marrow recovery, 11%). Overall survival, censored for crossover, was better with ibrutinib than ofatumumab (HR: 0.639; 95% CI: 0.418-0.975). With up to 71 months (median 41 months) of ibrutinib therapy, the safety profile remained consistent with prior reports; cumulatively, all-grade (grade ≥3) hypertension and atrial fibrillation occurred in 21% (9%) and 12% (6%) of patients, respectively. Only 16% discontinued ibrutinib because of adverse events (AEs). These long-term results confirm the robust efficacy of ibrutinib in relapsed/refractory CLL/SLL irrespective of high-risk clinical or genomic features, with no unexpected AEs. This trial is registered at www.clinicaltrials.gov (NCT01578707).
| INTRODUCTION
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are heterogenous diseases with outcomes that are affected by clinical status and genetic aberrations. 1 Lymphocytic Leukemia (IWCLL) guideline updates recommend testing for these high-risk factors to aid in treatment decisions. [2] [3] [4] [5] [6] Chemoimmunotherapy has been at the forefront of treatment of CLL/SLL in the past decade, resulting in improved progression-free survival (PFS) and overall survival (OS) outcomes for untreated patients requiring therapy. [7] [8] [9] [10] [11] Additionally, treatment of relapsed CLL/SLL with combination chemoimmunotherapy resulted in modest improvements in PFS and, in some cases, OS. [12] [13] [14] In the past, however, once patients became refractory to chemoimmunotherapy, especially those with early relapse or high-risk genomic features, treatment options were limited and survival time was short.
The introduction of targeted therapy to the armamentarium of CLL/SLL therapy has dramatically improved treatment outcomes in patients refractory to chemoimmunotherapy. Ibrutinib, a first-in-class, once-daily, covalent inhibitor of Bruton's tyrosine kinase (BTK; a B-cell receptor signaling kinase expressed by various hematopoietic cells, B-cell lymphomas, and leukemias), was one such therapy introduced in this relapsed and refractory CLL/SLL population that has since revolutionized therapy. 15 RESONATE was the first multicenter, open-label, randomized phase 3 study that compared ibrutinib to ofatumumab treatment outcomes in previously treated patients with CLL/SLL, leading to full FDA approval of ibrutinib (after prior accelerated approval), including in patients with del(17p). The analysis from the first report of this trial demonstrated that ibrutinib significantly improved PFS, OS, and overall response rates (ORR) compared with ofatumumab and was generally well tolerated. 16 RESONATE was also the first randomized trial that identified adverse events (AEs) associated with ibrutinib, such as atrial fibrillation and bruising, that have been followed long-term with BTK inhibitors. Herein, we report the final longterm follow-up efficacy and safety results of this landmark study, including analyses of subgroups with high-risk genomic features.
| METHODS

| Patients
Detailed eligibility criteria have been previously published. 16 
| Study Design
RESONATE was a randomized, multicenter, open-label, phase 3 study that evaluated the efficacy and safety of ibrutinib compared with ofatumumab in previously treated patients with relapsed or refractory CLL/SLL (clinicaltrials.gov number NCT01578707). Enrollment was from June 2012 to April 2013. Patients were randomly assigned 1:1 to receive either oral ibrutinib 420 mg once daily (until disease progression or unacceptable toxicity) or intravenous ofatumumab for up to 24 weeks at an initial dose of 300 mg at week one, followed by a dose of 2000 mg weekly for seven weeks and then every four weeks for 16 weeks. Stratification was by purine analog refractory status (defined as no response to or relapse within 12 months of last dose of purine analog) and presence or absence of del(17p). Based on durable responses in the ongoing pivotal phase 2 study PCYC-1102, 18 a protocol amendment was instituted in August 2013 to allow patients on the ofatumumab arm to cross over to receive ibrutinib. Following study closure, eligible patients could continue to receive ibrutinib treatment in a long-term extension study (PCYC-1145-LT; clinicaltrials.gov number NCT03229200). 
| Assessments
| Statistical methods
Long-term efficacy, including PFS, OS, and ORR, were assessed in the intent-to-treat population. PFS and ORR were based on investigator assessment (independent review committee assessments were performed only for the primary analysis). 16 PFS and OS (with and without censoring at crossover for ofatumumab patients) were analyzed using Kaplan-Meier methodology and hazard ratio (HR) was estimated using Cox regression model. In addition, the rank-preserving structural failure time (RPSFT) randomization-based model was employed to estimate the OS HR using counterfactual survival times that would have been observed in the absence of the extensive crossover.
Ofatumumab treatment was completed at the time of the primary analysis and reported in the previous report. Long-term safety was summarized by yearly interval for ibrutinib patients.
| Data sharing statement
Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at http://yoda. yale.edu.
| RESULTS
| Patient features
Baseline characteristics of patients randomized to ibrutinib (n = 195) or ofatumumab (n = 196) are shown in Table S1 . 19 Similar proportions of patients in the ibrutinib and ofatumumab arms had high-risk features, including del(17p) (32% and 33%, respectively), mutated TP53 (51% and 46%, respectively), del(11q) (33% and 31%, respectively), unmutated IGHV (73% and 63%, respectively), and complex karyotype (25% and 22%, respectively) ( Table S1 ). The majority of patients in both the ibrutinib and ofatumumab arms (86% and 79%, respectively) comprised the high-risk population, defined as having any of the fol- and Figure S1 ). The most common reasons for ibrutinib discontinuation prior to study closure were PD (72/195, 37%) and AEs (32/195, 16% P˂.0001; Figure 1A ) TP53 mutation (n = 68; Figure 2F ).
| Overall response
At extended follow-up, the cumulative ORR was 91% for ibrutinib.
The proportion of patients with a best response of CR/CRi increased over time to 11% with current follow-up ( Figure S3 ).
| Overall survival
With up to 6 years of post-randomization follow-up, median OS was 67.7 months (95% CI: 61.0-NE) in the ibrutinib arm and 65.1 months (95% CI: 50.6-NE) in the ofatumumab arm, irrespective of the extensive (68%) crossover to ibrutinib (HR: 0.810; 95% CI: 0.602-1.091) ( Figure S4A ). To compare OS outcomes between treatment arms accounting for the extensive crossover from ofatumumab to ibrutinib treatment, OS was analyzed with censoring at time of crossover and was better among patients initially assigned to ibrutinib than to ofatumumab (HR: 0.639; 95% CI: 0.418-0.975) ( Figure S4B) . A sensitivity analysis of OS adjusting for crossover based on the RPSFT method also showed continued OS benefit with ibrutinib compared with ofatumumab (HR: for ofatumumab. Similarly, a greater proportion of patients achieved clinically meaningful improvement in their EQ-5D-5L VAS Scores with ibrutinib (66%), than with ofatumumab (45%). Improvements in the FACIT-F score and the EQ-5D-5L VAS were largely maintained over time with ibrutinib ( Figures S5B, S5C ). Commonly reported grade ≥3 nonhematologic AEs included pneumonia (21%), hypertension (9%), urinary tract infection (7%), diarrhea (7%), and atrial fibrillation (6%). Overall, 19 patients (10%) in the ibrutinib arm experienced major hemorrhage. The prevalence of any grade ≥3 AEs with ibrutinib decreased after the first year and remained stable thereafter, with rates of 62%, 48%, 46%, 46%, 48%, and 32% during years zero to one, one to two, two to three, three to four, four to five, and five to six, respectively.
| Patient-reported outcomes
| Adverse events
In line with the overall prevalence, the prevalence of most grade ≥3 AEs of clinical interest with ibrutinib decreased over time and lung infection (4%). The prevalence of grade ≥3 atrial fibrillation was 4%, 0%, 2%, 2%, 1%, and 0% over years zero to one, one to two, two to three, three to four, four to five, and five to six, respectively ( Figure 3) . The prevalence of all-grade atrial fibrillation was 6%, 5%, 8%, 8%, 6%, and 4% over years zero to one, one to two, two to three, three to four, four to five, and five to six, respectively. Overall, 24 patients (12%) experienced atrial fibrillation of any grade, with a median duration of 10.0 days (range: 1-1323) for the events ( hypertension was 4%, 8%, 7%, 7%, 8%, and 11% over years zero to one, one to two, two to three, three to four, four to five, and five to six, respectively (Figure 3) . A total of 41 patients (21%) experienced hypertension of any grade ( Figure S8 Studies have shown that patients with del(17p) CLL treated with standard chemoimmunotherapy regimens have poor outcomes. 7, 12, [28] [29] [30] The 5-year follow-up data from the relapsed/ refractory cohort of the phase 2 PCYC-1102/1103 study with single-agent ibrutinib showed a lower PFS rate in patients with del(17p) than in patients without del(17p). 31 The 3-year follow-up of the RESONATE study reported the effectiveness of ibrutinib in patients regardless of del(17p). 19 In this final analysis of RESO-NATE with 6 years of follow-up, we confirm no significant difference in PFS for ibrutinib-treated patients with or without del(17p).
However, when data from patients with TP53 mutation were pooled with those with del(17p) in an exploratory analysis, we observed a lower PFS rate in the subgroup of patients with del(17p) and/or TP53 mutation than in patients without either of these abnormalities. Consistent with findings reported with earlier RESO-NATE follow-up, 32 the subset of ibrutinib-treated patients with both del(17p) and TP53 mutation trended to have shorter PFS relative to patients without either of these high-risk features. In contrast to the earlier report from RESONATE, PFS outcomes in patients with either del(17p) or TP53 mutation (but not both) were similar to that of patients with both del(17p) and TP53 mutation.
The small number of patients in these subgroups and the retrospective genetic/molecular analysis defining many of the subgroups may be potential limitations in the interpretation of these results. Development of acquired mutations in the B-cell receptor signaling pathway has been observed in patients relapsing during ibrutinib treatment and together with other as yet undefined mechanisms contributing to relapse may be associated with unstable genomes. Answers to these questions are being actively pursued in ongoing studies.
Unmutated IGHV and del(11q) have an adverse prognostic impact on patients with CLL. [2] [3] [4] [5] The negative impact from these markers has been substantially abrogated in the context of ibrutinib therapy, as
shown in this study and other studies. 28, 33 This is confirmed by the current results from RESONATE in which patients with del(11q) CLL appeared to have no decrement in benefit from continuous ibrutinib therapy. This is reflected in the median PFS for this group (n = 50), which was 60.7 months and appeared to be longer than the median PFS of the overall ibrutinib cohort. In addition, median PFS with ibrutinib treatment was similar between patients with mutated and unmutated IGHV. Thus, our follow-up data suggest that IGHV mutational status and del(11q) have no impact on the long-term outcomes with ibrutinib treatment.
The ORR with ibrutinib remains high with longer follow-up (91%)
and was similar to rates reported with a median follow-up of 44 months (91%). 19 The CR/CRi rates have increased over time with ibrutinib treatment, approaching a plateau beyond 3.5 years (9% and 11% with median 44 and 64 months of follow-up, respectively). This is consistent with deepening of response with continuous ibrutinib therapy for responding patients and is similar to the improved responses observed over time with longer follow-up in patients with relapsed/refractory CLL in the HELIOS study and in the phase 2 PCYC-1102/1103 study. 31, 34 Notably, the proportion of patients who reported clinically meaningful improvement in FACIT-F score was greater with ibrutinib than ofatumumab, and the improvement was maintained over time.
Assessment of long-term safety data is an important factor with continuous therapy, especially given the extended progression-free efficacy conferred by ibrutinib treatment. This update confirms that ibrutinib is well tolerated, and the prevalence of most grade ≥3 AEs of clinical interest decreased with each subsequent year of treatment, apart from hypertension, in which prevalence remained relatively consistent from year to year. During prolonged follow-up, the overall prevalence of treatment-emergent atrial fibrillation and hypertension of any grade were 12% and 21%, respectively. These rates were similar to those reported earlier in RESONATE with a median 44-month follow-up (11% and 20%, respectively). In addition, most of the patients who developed atrial fibrillation or hypertension had relevant risk factors for developing these complications. [35] [36] [37] It is important to note that the incidence of major hemorrhage with continued treatment was consistently low over the extended follow-up period. In addition, substantial proportions of ibrutinib-treated patients who experienced dose reductions or dose holds due to AEs were able to restart or remain on ibrutinib treatment (15% and 25% of these patients, respectively, remained on ibrutinib until study closure). There were no new or concerning AE trends or unexpected events noted with extended follow-up, and the safety profile appears consistent with earlier reports. ORCID Talha Munir https://orcid.org/0000-0002-2901-0769
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